SH3 domain containing ring finger 3Genealiases: POSH2 · SH3MD4
Q-omics provides the consensus-scored SH3RF3 profile across patient tissues and cancer cell-line models. SH3RF3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SH3RF3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SH3RF3 RNA expression shows 17,963 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where SH3RF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3RF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3RF3 survival associations across molecular data types. SH3RF3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3RF3 RNA expression–survival associations across cancer types. High SH3RF3 expression shows unfavorable associations in UVM, CESC, OV and BLCA, but favorable associations in KIRP and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SH3RF3 RNA expression.
This table summarizes SH3RF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SH3RF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3RF3 shows lower tumor expression in BLCA and LUSC and higher tumor expression in KIRC, COAD, KIRP and LIHC. The KIRC box plot shows higher SH3RF3 RNA expression in tumor versus normal tissue (log2 FC = +1.205, t-test p < 0.001).
This table shows molecular features associated with SH3RF3 in patient tissues and cancer cell lines. In patient samples, SH3RF3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3RF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
